Tag: Alzheimer’s
Panel Recommends Against Approval of Experimental Drug for Alzheimer Disease
FDA panel concluded there is not enough evidence to support the clinical effectiveness of aducanumab
Multinutrient Intervention Slows Cognitive Decline in Alzheimer Disease
Cognitive decline significantly reduced for Neuropsychological Test Battery five-item composite, memory, brain atrophy measures
Regulators Discuss Approval of New Alzheimer Disease Drug
Aducanumab does not cure or reverse Alzheimer disease; high dose may slow mental decline
Major Neurological Disorders on the Rise in the United States
Burden increasing largely due to aging of the U.S. population
Cognitive Disorders More Common in People Admitted for COVID-19
Genetic variations may put some individuals at higher risk for severe infection
Air Pollution Tied to Neurological Disorders in Seniors
Higher fine particulate matter tied to higher risk for Parkinson disease, Alzheimer disease
Rural Patients With Alzheimer Disease Have Shorter Survival
Rural versus urban patients also spend more time in nursing homes, receive less home health care
Daytime Noise Tied to Higher Dementia Risk
More daytime noise tied to 30 percent higher risk for mild cognitive impairment, Alzheimer disease
T2DM Links to Risk for Dementia Differ by Type, Glycemic Control
Dose-response association shows higher risk for dementia with HbA1c >87 versus <52 mmol/mol
Anticholinergic Meds May Raise Risk for Cognitive Decline
Effects significantly worse among individuals with risk factors for Alzheimer disease
